Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Receivables (2016 - 2023)

Spyre Therapeutics (SYRE) has disclosed Change in Receivables for 7 consecutive years, with -$163000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Change in Receivables rose 44.56% year-over-year to -$163000.0, compared with a TTM value of -$163000.0 through Sep 2024, up 67.79%, and an annual FY2023 reading of -$375000.0, up 14.77% over the prior year.
  • Change in Receivables was -$163000.0 for Q4 2023 at Spyre Therapeutics, up from -$1.5 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $21.5 million in Q1 2021 and bottomed at -$21.5 million in Q2 2021.
  • Average Change in Receivables over 3 years is $0.0, with a median of -$45000.0 recorded in 2023.
  • Peak annual rise in Change in Receivables hit 346.9% in 2023, while the deepest fall reached 880.53% in 2023.
  • Year by year, Change in Receivables stood at $815000.0 in 2021, then crashed by 136.07% to -$294000.0 in 2022, then soared by 44.56% to -$163000.0 in 2023.
  • Business Quant data shows Change in Receivables for SYRE at -$163000.0 in Q4 2023, -$1.5 million in Q3 2023, and $1.3 million in Q2 2023.